Improving treatment outcomes for patients with advanced bile duct cancer.

Who could benefit from this research

What this research studies

This research investigates a new treatment approach for patients with advanced intrahepatic cholangiocarcinoma (IHC), a type of bile duct cancer that often has a poor prognosis. The study compares the effectiveness of a combination of standard chemotherapy drugs, gemcitabine and oxaliplatin, with an additional regional chemotherapy agent, floxuridine, delivered directly to the liver. Patients will be randomly assigned to receive either the standard treatment or the combination treatment to determine which is more effective in improving survival rates. The study aims to provide better treatment options for patients whose cancer cannot be surgically removed.

Why it matters

Where this research is happening

• Sloan-Kettering Inst Can Research
  New York, United States Active

Researchers

• Principal investigator: Jarnagin, William Robert — Sloan-Kettering Inst Can Research
• Study coordinator: Jarnagin, William Robert

Related research

Other NIH-funded projects on the same topics.

• A new mouse model to study intrahepatic cholangiocarcinoma and its immunotherapy

  A new mouse model helps researchers understand intrahepatic cholangiocarcinoma and test immune-based treatments to improve outcomes.

  NIH research Sanford Burnham Prebys Medical Discovery Institute · La Jolla, United States · NIH-11413830

• Radiation plus a patient’s own immune cells to boost cholangiocarcinoma treatment

  This project tests a therapy that combines precise radiation and the patient’s own dendritic cells with immune drugs to help fight intrahepatic cholangiocarcinoma in people who cannot have surgery.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11408644

• New mouse model to improve immune therapy for intrahepatic bile duct (cholangiocarcinoma) cancer

  This project builds a new mouse model to help make immune-based treatments work better for people with intrahepatic cholangiocarcinoma, a type of bile duct liver cancer.

  NIH research Sanford Burnham Prebys Medical Discovery Institute · La Jolla, United States · NIH-11392619

• Understanding how tumor variety affects bile duct cancer (iCCA)

  Researchers will study how differences within a single tumor and between primary and metastatic sites influence disease progression and treatment response in intrahepatic cholangiocarcinoma, using human samples and mouse models.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11281627

• Using radiation and your own immune cells to boost immunotherapy for intrahepatic bile-duct (liver) cancer

  This approach combines focused liver radiation, injections of your own dendritic immune cells, and two immune drugs to try to help people with unresectable intrahepatic bile-duct cancer live longer without the disease getting worse.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11142663

• Noninvasive methods to identify mutations in liver cancer

  This study is looking for better ways to diagnose a type of liver cancer called intrahepatic cholangiocarcinoma (iCCA) by using noninvasive methods to check for important genetic changes, which can help doctors choose the best treatment for patients.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11092682

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.